Clinical Pharmacology in Psychiatry: Bridging the Experimental-Therapeutic Gap

Front Matter....Pages i-xviii
Front Matter....Pages 1-1
Utilization of psychotropic drugs in Sweden and the other Nordic countries....Pages 3-17
Patterns of use of psychotropic drugs in Spain in an international perspective....Pages 18-31
Heavy drug use among the elderly: prescription surveys in Manitoba....Pages 32-41
To what extent are inter- and intraregional differences in psychotropic drug use explained by demographic and socioeconomic factors?....Pages 42-58
Front Matter....Pages 59-59
Methodology of clinical trials: current issues....Pages 61-67
Practical aspects of the utilization of double-blind trials using adjusted doses of psychotropic drugs....Pages 68-73
Improving reliability and validity of adverse drug reaction assessment in psychopharmacology....Pages 74-82
Clinical evaluation of the cardiac effects of new psychotropic drugs....Pages 83-98
The implications of left ventricular performance for tricyclic antidepressant drug treatment....Pages 99-107
Registration of antidepressant drugs — views of a regulatory agency....Pages 108-113
Phase-4 studies in psychopharmacology — new antidepressant drugs....Pages 114-126
Front Matter....Pages 127-127
Overview: measuring plasma concentrations of psychotherapeutic drugs....Pages 129-135
Possible role of hydroxymetabolites in the action of neuroleptics....Pages 136-149
Radioreceptor assay for measurement of anticholinergic drugs in serum....Pages 150-164
Clinical effects related to the serum concentrations of thioridazine and its metabolites....Pages 165-174
Plasma levels of perphenazine related to clinical effect and extrapyramidal side-effects....Pages 175-181
Saliva haloperidol concentrations in schizophrenic patients: relation to serum haloperidol and prolactin concentrations....Pages 182-189
Front Matter....Pages 191-191
Significance of the serum lithium concentration and the treatment regimen for wanted and unwanted effects of lithium treatment....Pages 193-202
Hydroxy metabolite concentrations: role of renal clearance....Pages 203-216
Stereospecific 10-hydroxylation of nortriptyline — genetic aspects and importance for biochemical and clinical effects....Pages 217-226
Front Matter....Pages 191-191
The fate of amitriptyline and its metabolites, taking into account their binding in plasma....Pages 227-237
Protein binding of imipramine and related compounds....Pages 238-248
Front Matter....Pages 249-249
Relationships between receptor affinities of different antidepressants and their clinical profiles....Pages 251-267
Antidepressants and ∝-adrenoceptors....Pages 268-287
Antidepressants: effects on histaminic and muscarinic receptors....Pages 288-300
Antidepressants and components of the beta adrenoceptor system: studies on zimelidine....Pages 301-312
β-Adrenoceptor agonists enhance the functional activity of brain 5-hydroxytryptamine: relationship to antidepressant activity....Pages 313-326
Effects of antidepressant treatments on ‘whole body’ norepinephrine turnover....Pages 327-338
Association of 3H-imipramine binding with serotonin uptake and of 3H-desipramine binding with norepinephrine uptake: potential research tools in depression....Pages 339-348
Characterization of high-affinity antidepressant binding to rat and human brain....Pages 349-358
Front Matter....Pages 359-359
The human psychopharmacology of peptides related to ACTH and ∝-MSH....Pages 361-376
Clinical psychopharmacology of endorphins....Pages 377-385
GABA receptor agonists: pharmacological spectrum and clinical actions....Pages 386-394
Benzodiazepine receptor-mediated experimental ‘anxiety’ in rhesus monkeys after infusion of 3-carboethoxy-ß-carboline (ß-CCE)....Pages 395-401
Back Matter....Pages 403-413